近期论文

查看导师新发文章 （温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. New Engl. J. Med. 2005; 353:172-187. Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat. Rev. Cancer 2007; 7:332-344. Chan WW, Wise SC, Kaufman MD, Ahn Y-M, Ensinger CL, Haack T, Hood MM, Jones J, Lord JW, Lu WP, Miller D, Patt WC, Smith BD, Petillo PA, Rutkoski TJ, Telikepalli H, Vogeti L, Yao T, Chun L, Clark R, Evangelista P, Gavrilescu LC, Lazarides K, Zaleskas VM, Stewart L, Van Etten RA, Flynn DL. Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell 2011; 19:556-568. PMC3077923 Okimoto RA, Van Etten RA. Navigating the road toward optimal initial therapy for chronic myeloid leukemia. Curr. Opin. Hematol. 2011; 18:89-97. PMC3496274 Lu Y-F, Betancur M, Lazarides K, Klingemann H, Van Etten RA. Distinct graft-vs-leukemic stem cell effect of early or delayed donor leukocyte infusion in a mouse chronic myeloid leukemia model. Blood 2012; 119:273-284. PMC3251232 Walz C, Ahmed W, Lazarides K, Betancur M, Patel N, Hennighausen L, Zaleskas VM, Van Etten RA. Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2V617F. Blood 2012; 119(15):3550-3560. PMC3325042 Cortes J, Lipton JH, Rea D, Digumarti R, Chuah C, Nanda N, Benichou AC, Craig AR, Michallet M, Nicolini FE, Kantarjian H, Ailawadhi S, Akard L, Baer M, Baccarani M, Emmons R, Etienne G, Guerci A, Guilhot F, Hellmann A, Huguet-Rigal F, Khoury H, Laneuville P, Coutre PL, Legros L, Leitner A, Maloisel F, Marin D, Masszi T, Parikh P, Rivera C, Rousselot P, Facon T, Van Etten R, Warzocha K,Wetzler M, Wiernik P. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood. 2012;120(13):2573-2580. Ahmed W, Van Etten RA. Alternative approaches to eradicating the malignant clone in CML: TKI combinations and beyond. Hematology Am Soc Hematol Educ Program 2013;2013:189-200. Mughal TI, Girnius S, Rosen S, Kumar S, Weistner A, Abdel-Wahab O, Kiladjian J-J, Wilson WH, Van Etten RA. Emerging therapeutic paradigms to target the deregulated JAK/STATpathways in hematologic malignancies. Leuk. Lymphoma 2013; Epub Nov 11. doi:10.3109/10428194.2013.863307. Ahmed W, Van Etten RA. Signal transduction in the chronic leukemias: Implications for targeted therapies. Curr. Hematol. Malig. Rep. 2013;8(1):71-80. NIHMSID 434916 Kantarjian H, et al. The price of drugs for chronic myeloid leukemia (CML); A reflection of the unsustainable prices of cancer drugs: From the perspective of a large group of CML experts. Blood 2013; 121:4439-4442. Klingemann H, Grodman C, Cutler E, Duque M, Kadidlo D, Klein A, Sprague K, Miller K, Comenzo R, Kewalramani T, Yu N, Van Etten RA, McKenna D. Autologous stem celltransplant recipients tolerate haploidentical related-donor natural killer cell enriched infusions. Transfusion 2013;53(2):412-418. NIHMS378771 Mughal TI, Girnius S, Rosen S, Kumar S, Weistner A, Abdel-Wahab O, Kiladjian J-J, Wilson WH, Van Etten RA. Emerging therapeutic paradigms to target the deregulated JAK/STAT pathways in hematologic malignancies. Leuk. Lymphoma 2013; Epub Nov 11. doi:10.3109/10428194.2013.863307.